Researchers identified 10 protein-based tumor subtypes across five cancer types, including subtypes representing immune cell features in the tumor microenvironment.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.
Researchers demonstrated the importance of integrating mutational and transcriptomic profiles to improve understanding of AML and MDS patients' prognosis.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
While NanoString will commercialize its nCounter for research use applications, Veracyte will move its current assays onto the platform to reach a global audience.
The new method, called sci-Plex, combines nuclear hashing and improved single-cell combinatorial indexing RNA-seq to profile the transcriptional response of single cells.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
In Science this week: approach to visualize 3D genome structure in single cells, RNA interference knockdown screens to examine genetic origins of beetle horns and insect wings, and more.
Using RNA sequencing, researchers profiled gene expression patterns in cutaneous leishmaniasis lesions, identifying a handful of genes with treatment-associated expression.
